Pharmaceutical industry groups asked the FDA for more clarity on when a single pivotal trial plus confirmatory evidence is sufficient for approval. The push reflects ongoing uncertainty in how confirmatory evidence should be defined and what examples regulators consider acceptable for bridging across populations or endpoints. For biotech sponsors, the request impacts study design risk—particularly for programs that cannot afford multiple large pivotal trials or that are facing time and budget constraints. The FDA’s response will likely be closely monitored because guidance on evidentiary sufficiency can directly influence development timelines and how companies allocate resources between Phase 2 expansion and Phase 3 execution.